DK3086784T3 - Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose - Google Patents
Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose Download PDFInfo
- Publication number
- DK3086784T3 DK3086784T3 DK14815747.2T DK14815747T DK3086784T3 DK 3086784 T3 DK3086784 T3 DK 3086784T3 DK 14815747 T DK14815747 T DK 14815747T DK 3086784 T3 DK3086784 T3 DK 3086784T3
- Authority
- DK
- Denmark
- Prior art keywords
- bicalutamid
- glycogenose
- exocytose
- analogue
- treatment
- Prior art date
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000007345 glycogen storage disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382541 | 2013-12-23 | ||
| PCT/EP2014/078745 WO2015097088A1 (en) | 2013-12-23 | 2014-12-19 | Bicalutamide analogs or (s)-bi calutam ide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3086784T3 true DK3086784T3 (da) | 2019-06-17 |
Family
ID=50238086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14815747.2T DK3086784T3 (da) | 2013-12-23 | 2014-12-19 | Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11571407B2 (da) |
| EP (1) | EP3086784B9 (da) |
| JP (1) | JP6546923B2 (da) |
| KR (1) | KR102128145B1 (da) |
| CN (1) | CN105828811B (da) |
| AU (1) | AU2014372690B2 (da) |
| CA (1) | CA2934772C (da) |
| CL (1) | CL2016001210A1 (da) |
| DK (1) | DK3086784T3 (da) |
| ES (1) | ES2732308T3 (da) |
| HU (1) | HUE043959T2 (da) |
| IL (1) | IL245789B (da) |
| LT (1) | LT3086784T (da) |
| MX (1) | MX374840B (da) |
| MY (1) | MY182903A (da) |
| NZ (1) | NZ720499A (da) |
| PH (1) | PH12016501168A1 (da) |
| PL (1) | PL3086784T3 (da) |
| PT (1) | PT3086784T (da) |
| RU (1) | RU2685269C2 (da) |
| WO (1) | WO2015097088A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US20190076376A1 (en) * | 2015-07-10 | 2019-03-14 | University Of Miami | Methods for treating mucopolysaccharidosis |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| CA3010205A1 (en) | 2015-12-30 | 2017-07-06 | Amicus Therapeutics, Inc. | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| JP7302871B2 (ja) * | 2016-04-21 | 2023-07-04 | ベイラー カレッジ オブ メディスン | リソソーム蓄積障害およびリソソーム機能不全によって特徴付けられる障害を治療するための組成物および方法 |
| PT3624831T (pt) | 2017-05-15 | 2023-07-04 | Amicus Therapeutics Inc | Alfa-glucosidase ácida humana recombinante |
| US12239693B2 (en) | 2018-04-27 | 2025-03-04 | The Medical College Of Wisconsin, Inc. | Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US12565643B2 (en) | 2019-09-18 | 2026-03-03 | The Medical College Of Wisconsin, Inc. | Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use |
| CN112807302A (zh) * | 2021-02-05 | 2021-05-18 | 重庆西南果品营养研究院 | 橘皮素在制备控制人体血尿酸水平的药物或食品中的新用途 |
| CN115678934A (zh) * | 2022-11-07 | 2023-02-03 | 陕西科技大学 | 一种利用大肠杆菌和谷氨酸棒杆菌共培养合成圣草酚的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE468159B (sv) | 1991-03-25 | 1992-11-16 | Alfa Laval Thermal Ab | Foerfarande foer att belaegga vaermeoeverfoeringsplattor i en plattvaermevaexlare med ett skikt av ytskyddande material |
| US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| US6160011A (en) * | 1997-05-30 | 2000-12-12 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
| AU7723198A (en) | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| EA200401121A1 (ru) * | 2002-02-28 | 2005-10-27 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Необратимые селективные модуляторы андрогенового рецептора и способы их применения |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US20110237664A1 (en) | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| CA2644429C (en) * | 2006-03-14 | 2014-07-29 | Lidds Ab | Bioresorbable controlled-release composition |
| EP2533050B3 (en) * | 2006-05-16 | 2015-06-24 | Amicus Therapeutics, Inc. | Treatment Options For Fabry Disease |
| EA024161B1 (ru) | 2006-07-12 | 2016-08-31 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Фармацевтические композиции, содержащие замещенные ациланилиды |
| WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| PL3395372T3 (pl) * | 2009-02-20 | 2022-07-25 | EnhanX Biopharm Inc. | Układ do dostarczania leków na bazie glutationu |
| US20120277158A1 (en) * | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| AU2011223706A1 (en) | 2010-03-05 | 2012-09-20 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in Fabry disease |
| CN103764824B (zh) * | 2011-06-20 | 2018-04-24 | 西奈山医学院 | 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法 |
| US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
-
2014
- 2014-12-19 ES ES14815747T patent/ES2732308T3/es active Active
- 2014-12-19 CA CA2934772A patent/CA2934772C/en active Active
- 2014-12-19 MX MX2016008283A patent/MX374840B/es active IP Right Grant
- 2014-12-19 WO PCT/EP2014/078745 patent/WO2015097088A1/en not_active Ceased
- 2014-12-19 CN CN201480069002.4A patent/CN105828811B/zh active Active
- 2014-12-19 EP EP14815747.2A patent/EP3086784B9/en active Active
- 2014-12-19 RU RU2016125883A patent/RU2685269C2/ru active
- 2014-12-19 PT PT14815747T patent/PT3086784T/pt unknown
- 2014-12-19 US US15/102,358 patent/US11571407B2/en active Active
- 2014-12-19 LT LTEP14815747.2T patent/LT3086784T/lt unknown
- 2014-12-19 NZ NZ720499A patent/NZ720499A/en unknown
- 2014-12-19 JP JP2016540621A patent/JP6546923B2/ja active Active
- 2014-12-19 AU AU2014372690A patent/AU2014372690B2/en active Active
- 2014-12-19 DK DK14815747.2T patent/DK3086784T3/da active
- 2014-12-19 MY MYPI2016000977A patent/MY182903A/en unknown
- 2014-12-19 HU HUE14815747A patent/HUE043959T2/hu unknown
- 2014-12-19 KR KR1020167020121A patent/KR102128145B1/ko active Active
- 2014-12-19 PL PL14815747T patent/PL3086784T3/pl unknown
-
2016
- 2016-05-19 CL CL2016001210A patent/CL2016001210A1/es unknown
- 2016-05-23 IL IL245789A patent/IL245789B/en active IP Right Grant
- 2016-06-16 PH PH12016501168A patent/PH12016501168A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11571407B2 (en) | 2023-02-07 |
| HUE043959T2 (hu) | 2019-09-30 |
| MY182903A (en) | 2021-02-05 |
| PT3086784T (pt) | 2019-06-27 |
| IL245789B (en) | 2020-01-30 |
| KR20160095174A (ko) | 2016-08-10 |
| RU2016125883A3 (da) | 2018-07-31 |
| MX374840B (es) | 2025-03-06 |
| US20160317489A1 (en) | 2016-11-03 |
| PH12016501168B1 (en) | 2016-07-18 |
| CL2016001210A1 (es) | 2016-12-16 |
| CN105828811A (zh) | 2016-08-03 |
| EP3086784B9 (en) | 2019-10-16 |
| MX2016008283A (es) | 2016-09-08 |
| AU2014372690B2 (en) | 2019-10-03 |
| CN105828811B (zh) | 2022-04-08 |
| CA2934772A1 (en) | 2015-07-02 |
| WO2015097088A1 (en) | 2015-07-02 |
| RU2685269C2 (ru) | 2019-04-17 |
| JP6546923B2 (ja) | 2019-07-17 |
| JP2017503781A (ja) | 2017-02-02 |
| CA2934772C (en) | 2021-04-27 |
| RU2016125883A (ru) | 2018-01-30 |
| LT3086784T (lt) | 2019-06-25 |
| PH12016501168A1 (en) | 2016-07-18 |
| PL3086784T3 (pl) | 2019-09-30 |
| NZ720499A (en) | 2020-04-24 |
| EP3086784A1 (en) | 2016-11-02 |
| IL245789A0 (en) | 2016-07-31 |
| AU2014372690A1 (en) | 2016-06-09 |
| ES2732308T3 (es) | 2019-11-21 |
| EP3086784B1 (en) | 2019-03-27 |
| KR102128145B1 (ko) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3086784T3 (da) | Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose | |
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| CY2019015I2 (el) | Χρηση πυριτικου ζιρκονιου για τη θεραπεια της υπερκαλιαιμιας | |
| PT3181119T (pt) | Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca | |
| IL246141A0 (en) | Methods for adhering tissue surfaces and materials and biomedical uses thereof | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK4374873T3 (da) | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande | |
| DK3195793T3 (da) | Forbedringer i eller relateret til oftalmologi | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| PT2898885T (pt) | Derivados de pirrolopirimidina para utilização no tratamento de infeções virais | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| HRP20180838T1 (hr) | Formuliranje deksmedetomidina u obliku predsmjese | |
| DK2968091T3 (da) | Forbindelse til brug ved hudbeskyttelse | |
| DK3143011T3 (da) | Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
| DK2825181T3 (da) | Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom | |
| IL247354A0 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| EP2821053A4 (en) | CLEANSING COMPOSITION FOR THE SKIN | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| LT3226854T (lt) | Aminorūgštimi paremta kompozicija skirta fibroelastino atkūrimui odos jungiamuosiuose audiniuose | |
| PL3096767T3 (pl) | Kompozycja zawierająca okrę do zastosowania w zmniejszaniu wchłaniania tłuszczu pokarmowego |